Time To Grow: SK Bioscience Eyes US Vaccine, CGT Acquisitions This Year

CEO Doesn’t Believe CGT Market Faces Overcapacity

 
• By Jung Won Shin

SK Bioscience CEO outlines the progress the firm is making in its growth acceleration strategy, which involves aggressive M&As and other investment plans.

Jae-Yong Ahn, CEO of SK Bioscience
SK Bioscience's Aggressive Investment Could Delay Its Turnaround For Few Years • Source: SK Bioscience

More from South Korea

More from Focus On Asia